Licensing Agreements
Crucell announces PER.C6 and ceNOS licensing agreements with BIOA&D
Published in Gene Therapy Weekly, June 22nd, 2006
The first relates to the use of Crucell's PER.C6 technology in the production of adenoviral vectors expressing ceNOS (constituted endothelial nitric oxide synthase) for the treatment of cardiovascular disease. In addition, the parties have signed an agreement that allows BIOA&D to use Crucell's patented ceNOS gene therapy technology.
ceNOS is an enzyme that produces nitric oxide, a molecule known to be beneficial in various applications for cardiovascular disease. Crucell developed...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2006-06-22)
More Articles from Gene Therapy Weekly
- Cancer Gene Therapy
RNA interference down-regulation influences lung cancer cell growth and apoptosis - Drug Delivery
Delivery of antisense oligonucleotides is increased by methacrylic acid copolymers - Drug Delivery
Oligonucleotide-polyethylenimine complexes target retinal cells - Gene Silencing
RNAi-mediated gene silencing achieved in non-human primates - Gliomas
Glioma cell migration is decreased by annexin 2 knockdown - Adverse Drug Reaction
Non-small cell lung cancer combination treatment can cause thrombocytopenia - More from this issue of Gene Therapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
